SOURCE: Arrayit Corporation

Arrayit Corporation

October 15, 2009 07:00 ET

Will Arrayit Technology Identify Life on Mars?

European Space Agency Using Arrayit Technology for the ExoMars Mission, Aurora Program

SUNNYVALE, CA--(Marketwire - October 15, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces a collaboration with the European Space Agency.

Since 1877, when the Italian astronomer Giovanni Schiaparelli first observed the Canals, people have wondered whether there is life on Mars. Today, the European Space Agency's ExoMars Mission Aurora Program is using Arrayit Technology to create the Life Marker Chip (LMC) to search for evidence of past and present life on Mars. The technology will examine Martian soil samples from the surface and up to 2 meters below the surface where organic molecules may be better preserved.

The LMC is an antibody microarray based instrument which aims to detect a number of specific targets which may be present in the sample, and is the only instrument which can specifically identify large organic molecules. The microarray is printed on to thin film optical waveguides by the Arrayit SpotBot® microarray printer. Arrayit was determined to be the only viable alternative after a study of all microarray manufacturing equipment. The ExoMars mission is currently planned for launch in 2011 and landing in 2013.

"We are pleased to be chosen for this mission-critical contribution," said Rene Schena, CEO of Arrayit. "This demonstrates the versatility and durability of our microarray approach to identifying organics at the molecular level."

Back home on planet Earth, Arrayit's microarray technology is being employed in the discovery of the reactions within cells that lead to specific diseases. This revolution in healthcare will, in turn, lead to rapid diagnostics and early detection of cancer and auto-immune disease.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.

Contact Information